Technology Search
Your search returned '14' results
-
Pregabalin (Lyrica) for partial onset epilepsy – monotherapy
Agency: NHSC
Name: Pregabalin (Lyrica)
Technology Type: Drug
Patient Indications: Epilepsy: partial onset seizures with or without secondary generalisation – monotherapy.
Entered On: October 2 2009
-
Uscom 1A non-invasive haemodynamic monitor
Agency: NHSC
Name: Uscom 1A
Technology Type: Device
Patient Indications: Adults or children with severe sepsis.
Entered On: October 2 2009
-
EOS low dose 2D/3D x-ray imaging system
Agency: NHSC
Name: EOS low dose 2D/3D x-ray imaging system
Technology Type: Procedure Diagnostics Device
Patient Indications: Patients requiring x-ray imaging, particularly: • orthopaedic patients, e.g. with spinal conditions such as scoliosis or vertebral dislocation, and those requiring limb reconstruction; • paediatric patients.
Entered On: October 5 2009
-
TransApical Transcatheter Aortic Valve Implantation
Agency: Agenas (COTE)
Name: Edwards Sapien (TM)
Technology Type: Device
Patient Indications: The procedure TA-TAVI is indicated in patients suffering from severe aortic stenosis with a high risk of death during a conventional surgical procedure. These patients are generally elderly and without treatment have a high risk of death. Their existing co-morbidities influence the risk/benefit ratio of a surgical intervention to replace the aortic valve (cardiopulmonary by-pass, CPB).
Entered On: October 7 2009
-
Tele-Home Care system based on Digital Video Broadcasting Terrestrial technology
Agency: Agenas (COTE)
Name: KeepInTouch system (R)
Technology Type: Device
Patient Indications: Tele-Home Care system based on Digital Video Broadcasting Terrestrial (DVB-T) technology is aimed at chronic patients, out patients after discharge from hospital, elderly people and at risk patients (patients with cardiac failure, diabetes and/or hypertension) who require monitoring within the home. Homecare assistance is aimed at those patients who require assistance at home, this includes house visits by GPs, nurses, rehabilitation and welfare service. It is graded on the specialist care required by the patient. At present there are three indications which patients need to fullfill, as follows: - Patient with hypertension (usually with few symptoms): he/she has to came to the hospital for examination every six months. Between visits it is suggested that the patients visit their doctor’s surgery monthly, to assess the effectiveness of their antihypertension medication. - Patient with heart failure (which is a more serious, frequently symptomatic pathology): the pathway is similar to the first indication, however the consultant would normally be a cardiologist, not a family doctor. For this type of patient it is important that the body weight is linked to an increased fluid intake which is characteristic of the disease of marks its progression or if the therapy is not sufficient a rapid intervention needs to be made. - Diabetic patient: the control periods needed for insulin or non insulin-dependant patients is different and varies from two to three months. The patient however is able to test their own glucose levels more than once within a day period and decide depending on the results how much insulin is needed. The patient also needs to acquire data in between visits to present to the diabetic center at follow up and discuss these from one visit to the next.
Entered On: October 7 2009
-
Minimally invasive treatment for atrial fibrillation by high intensity ultrasound (HIFU) ablation
Agency: Agenas (COTE)
Name: Epicor LP (TM)
Technology Type: Device
Patient Indications: The technology is aimed at patients who suffer from atrial fibrillation (AF) and who have shown resistance to other pharmacological therapies and/or have received treatment by transcatheter ablation which was ineffective.
Entered On: October 7 2009
-
Vernakalant (IV) for Atrial Fibrillation
Agency: IHSP
Name: KYNAPID TM, RSD 1235
Technology Type: Drug
Patient Indications: Patients with short-duration atrial fibrillation
Entered On: October 12 2009
-
Pixantrone for Relapsed aggressive non-Hodgkin's lymphoma (third-line)
Agency: IHSP
Name: Pixantrone, BBR 2278, BBR 2788
Technology Type: Drug
Patient Indications: Patients with relapsed and aggressive non-Hodgkin's lymphoma (third-line)
Entered On: October 12 2009
-
Aliskiren/Amlodipine association for treatment of hypertension
Agency: IHSP
Name: Aliskiren/Amlodipine
Technology Type: Drug
Patient Indications: Hypertension
Entered On: October 13 2009
-
Aliskiren/Valsartan association for treatment of hypertension
Agency: IHSP
Name: VALTURNA
Technology Type: Drug
Patient Indications: Hypertension
Entered On: October 13 2009
-
β-cell lymphoma vaccine (BIOVAXID) for follicular non-Hodgkin’s lymphoma
Agency: IHSP
Name: BIOVAXID
Technology Type: Drug
Patient Indications: Follicular non-Hodgkin’s lymphoma
Entered On: October 14 2009
-
Everolimus (Afinitor®) for advanced/metastatic kidney cancer
Agency: LBI -HTA
Name: everolimus, afinitor®
Technology Type: Drug
Patient Indications: for the treatment of patients with metastatic or advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.
Entered On: October 15 2009
-
Cetuximab (Erbitux®) in EGRF- expressing Non-Small Cell Lung Cancer
Agency: LBI -HTA
Name: Cetuximab (Erbitux®)
Technology Type: Drug
Patient Indications: Cetuximab in combination with double-agent platinum-based chemotherapy (cisplatin and vinorelbine) is indicated for first-line treatment of advanced and recurrent non-small cell lung cancer (NSCLC). Patients eligible for the cetuximab chemotherapy regimen are ≥ 18 years of age, have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 2 and suf-fer from EGFR-expressing non-small cell lung cancer.
Entered On: October 15 2009
-
Everolimus for autosomal dominant polycystic kidney disease with renal impairment
Agency: NHSC
Name: Everolimus
Technology Type: Drug
Patient Indications: • Autosomal dominant polycystic kidney disease with renal impairment (chronic kidney disease stage II and III).
Entered On: October 20 2009